Covered recipient · General Payments record
CRYSTAL M PROUD
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology with Special Qualifications in Child Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$155,434.78
166 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $88,419.00 | 18 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,434.87 | 22 |
| Travel and Lodging | $18,176.31 | 38 |
| Honoraria | $11,400.00 | 2 |
| Food and Beverage | $5,004.60 | 86 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Sarepta Therapeutics, Inc. | $106,666.37 | 77 |
| Biogen, Inc. | $26,948.44 | 62 |
| Novartis Gene Therapies, Inc. (fka AveXis, Inc.) | $17,387.72 | 19 |
| PFIZER INC. | $3,766.66 | 3 |
| F. Hoffmann-La Roche AG | $609.12 | 2 |
| Supernus Pharmaceuticals, Inc. | $36.31 | 2 |
| Genentech USA, Inc. | $20.16 | 1 |
Page 4 of 4; records 151–166 of 166 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CRYSTAL M PROUD
NPI 1013159177 · CMS profile ID 990357
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology with Special Qualifications in Child Neurology
NORFOLK, VA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–166 of 166 matching records. This page contains 16 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1013159177?year=2023&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CRYSTAL M PROUD, NPI 1013159177, CMS profile ID 990357. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–166 of 166 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013159177?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). CRYSTAL M PROUD, NPI 1013159177, CMS profile ID 990357. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–166 of 166 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013159177?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- CRYSTAL M PROUD, NPI 1013159177, CMS profile ID 990357, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–166 of 166 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1013159177?year=2023&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
166 matching records · $155,434.78 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–166 of 166.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics, Inc. | $48.00 | 01/23/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053377575 | CMS |
| Sarepta Therapeutics, Inc. | $117.80 | 01/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053375893 | CMS |
| Sarepta Therapeutics, Inc. | $84.46 | 01/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053375993 | CMS |
| Sarepta Therapeutics, Inc. | $300.00 | 01/14/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053376013 | CMS |
| Sarepta Therapeutics, Inc. | $315.27 | 01/14/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053376025 | CMS |
| Sarepta Therapeutics, Inc. | $1,460.44 | 01/14/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053376161 | CMS |
| Sarepta Therapeutics, Inc. | $9,625.00 | 01/14/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053376235 | CMS |
| Sarepta Therapeutics, Inc. | $11.14 | 01/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053376259 | CMS |
| Sarepta Therapeutics, Inc. | $27.13 | 01/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053377493 | CMS |
| Sarepta Therapeutics, Inc. | $40.26 | 01/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053377525 | CMS |
| Sarepta Therapeutics, Inc. | $48.00 | 01/14/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053377569 | CMS |
| Sarepta Therapeutics, Inc. | $48.70 | 01/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053377589 | CMS |
| Sarepta Therapeutics, Inc. | $48.70 | 01/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053377597 | CMS |
| Biogen, Inc. | $0.89 | 01/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012207609 | CMS |
| Biogen, Inc. | $18.88 | 01/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012220641 | CMS |
| Genentech USA, Inc. | $20.16 | 01/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040334229 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $11,520.46 | 5 |
| PY2025 | Principal investigator | $993,690.21 | 314 |
| PY2024 | Recipient | $4,416.31 | 9 |
| PY2024 | Principal investigator | $1,018,096.66 | 363 |
| PY2023 | Recipient | $2,728.41 | 7 |
| PY2023 | Principal investigator | $1,418,328.74 | 414 |
| PY2022 | Recipient | $1,000.00 | 2 |
| PY2022 | Principal investigator | $861,002.84 | 172 |
| PY2021 | Recipient | $13,737.07 | 7 |
| PY2021 | Principal investigator | $1,336,696.73 | 92 |
| PY2020 | Principal investigator | $357,902.35 | 73 |
| PY2019 | Recipient | $4,500.00 | 1 |
| PY2019 | Principal investigator | $102,799.06 | 16 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
319 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.06 | 12/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223615916 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $182.46 | 12/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223615918 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.72 | 12/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223615920 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.84 | 12/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223615922 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,620.00 | 12/19/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614189 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $271.09 | 12/19/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614191 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $120.00 | 12/19/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614193 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $120.00 | 12/19/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614195 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $120.00 | 12/19/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614201 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $271.10 | 12/19/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614203 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $500.00 | 12/19/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614205 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $171.87 | 12/19/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614207 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $271.09 | 12/19/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614209 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,620.00 | 12/19/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614211 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $271.09 | 12/19/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614213 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $810.00 | 12/19/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223615924 |
| Principal investigator 1 | Biogen, Inc. | $2,765.00 | 12/18/2025 | Covered Recipient Teaching Hospital Childrens Hospital Of The Kings Da | A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam | No dispute reported | 06/30/2026 | 1236947946 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $810.00 | 12/17/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9005-101 | No dispute reported | 06/30/2026 | 1223611795 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $675.00 | 12/17/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9005-101 | No dispute reported | 06/30/2026 | 1223611797 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $337.00 | 12/17/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9005-101 | No dispute reported | 06/30/2026 | 1223611799 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,620.00 | 12/17/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9005-101 | No dispute reported | 06/30/2026 | 1223611801 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,350.00 | 12/17/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9005-101 | No dispute reported | 06/30/2026 | 1223611803 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $495.00 | 12/16/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP PLLC | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249093842 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,883.05 | 12/11/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614185 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $135.28 | 12/08/2025 | Non-covered Recipient Entity CHILDRENS HOSPITAL OF THE KINGS DAUGHTERS INC | Phase IIIb, Open-label, Single-arm, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally (1.2 x 10^14 Vector Genomes) to Participants 2 to 12 Years of Age With Spinal Muscular Atrophy (SMA) Who Have Dis | No dispute reported | 06/30/2026 | 1190305137 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20.00 | 12/01/2025 | Non-covered Recipient Entity CHILDRENS HOSPITAL OF THE KINGS DAUGHTERS INC | Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 IT or OAV101 IV in Clinical Trials | No dispute reported | 06/30/2026 | 1190305131 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $11,341.16 | 12/01/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614187 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $11,341.16 | 12/01/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614197 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $11,341.16 | 12/01/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614199 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 11/27/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611659 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $248.07 | 11/13/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610787 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,041.20 | 11/12/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-401 | No dispute reported | 06/30/2026 | 1223609723 |
| Recipient | Novartis Pharmaceuticals Corporation | $286.19 | 11/06/2025 | Covered Recipient Physician | STRENGTH | No dispute reported | 06/30/2026 | 1190293717 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 11/06/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611651 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 11/06/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611653 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 11/06/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611655 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 11/06/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611657 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,422.09 | 11/06/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611661 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $60.50 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610771 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.13 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610773 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $176.64 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610789 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.06 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610791 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.72 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610793 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.84 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610795 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.06 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610797 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $19.20 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610799 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.92 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610801 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.35 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610803 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $16.27 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610805 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.28 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610807 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.61 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610809 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $4.36 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610811 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.27 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610813 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.58 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610815 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.36 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610817 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $14.96 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613402 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.72 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613404 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.88 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613406 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $4.50 | 11/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613408 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 10/31/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223616076 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 10/31/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223616078 |
| Principal investigator 1 | Genentech, Inc. | $7,218.00 | 10/28/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP PLLC | A PHASE II STUDY OF SATRALIZUMAB IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1211586295 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $8,422.66 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9004-102 | No dispute reported | 06/30/2026 | 1223611805 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $674.00 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9004-102 | No dispute reported | 06/30/2026 | 1223611807 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $648.00 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9004-102 | No dispute reported | 06/30/2026 | 1223611809 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $36.90 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223613332 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $6.00 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223613334 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $5.40 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223613336 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $52.38 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223613338 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $46.08 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223613340 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $22.02 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223613342 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $37.62 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223613344 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $214.75 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223613346 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $36.75 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223613348 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $277.41 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223613350 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $236.40 | 10/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223613352 |
| Principal investigator 1 | Biogen, Inc. | $89,381.00 | 10/13/2025 | Non-covered Recipient Entity CHKD Main Hospital | A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old | No dispute reported | 06/30/2026 | 1236946972 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,422.09 | 10/06/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223616074 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,155.64 | 10/03/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613356 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,323.00 | 10/03/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613358 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,164.00 | 10/01/2025 | Non-covered Recipient Entity CHILDRENS HOSPITAL OF THE KINGS DAUGHTERS INC | A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy | No dispute reported | 06/30/2026 | 1190305127 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $1,077.98 | 09/26/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP PLLC | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249093690 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $75.90 | 09/23/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223610465 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $86.58 | 09/23/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223610467 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $18.02 | 09/23/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223615882 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $78.57 | 09/23/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223615884 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $13.71 | 09/23/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223615886 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $32.52 | 09/23/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223615888 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $56.46 | 09/23/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223615890 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $18.81 | 09/23/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223615892 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $539.85 | 09/23/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223615894 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $36.75 | 09/23/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223615896 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $9.60 | 09/15/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610461 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $58.88 | 09/15/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610463 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 09/15/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614029 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $7,158.78 | 09/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9003-301 | No dispute reported | 06/30/2026 | 1223612553 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $1,077.98 | 08/29/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP PLLC | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249093647 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $705.00 | 08/29/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP PLLC | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249093649 |
| Principal investigator 1 | Genentech, Inc. | $2,921.54 | 08/27/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP PLLC | A PHASE II STUDY OF SATRALIZUMAB IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1211586291 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,883.05 | 08/25/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614953 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 08/25/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614957 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $110.25 | 08/22/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223614939 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,695.53 | 08/20/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-LGMD-501-NHS | No dispute reported | 06/30/2026 | 1223611465 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 08/14/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223614955 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $9,672.11 | 08/06/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9004-102 | No dispute reported | 06/30/2026 | 1223611543 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $26,666.15 | 07/31/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223609527 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $1,040.00 | 07/26/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP PLLC | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249093565 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,834.65 | 07/25/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-401 | No dispute reported | 06/30/2026 | 1223612531 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $10,125.00 | 07/23/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9005-101 | No dispute reported | 06/30/2026 | 1223611567 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $3,375.00 | 07/23/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9005-101 | No dispute reported | 06/30/2026 | 1223611569 |
| Principal investigator 1 | CSL Behring | $1,000.00 | 07/14/2025 | Non-covered Recipient Entity Children'S Specialty Group, Pllc | Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP | No dispute reported | 06/30/2026 | 1252667135 |
| Principal investigator 1 | CSL Behring | $1,250.00 | 07/14/2025 | Non-covered Recipient Entity Children'S Specialty Group, Pllc | Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP | No dispute reported | 06/30/2026 | 1252667137 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.24 | 07/14/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223612453 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.28 | 07/14/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223612455 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.02 | 07/14/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223612457 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $9.60 | 07/14/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223612459 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $29.44 | 07/14/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223612461 |
| Principal investigator 1 | Genentech, Inc. | $16,139.00 | 07/11/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP PLLC | A PHASE II STUDY OF SATRALIZUMAB IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1211586287 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $81,807.88 | 07/11/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9003-301 | No dispute reported | 06/30/2026 | 1223611467 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $240.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609515 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $240.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609517 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $240.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609519 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $240.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609521 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $240.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609523 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $240.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609525 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $81.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609529 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $95.76 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609531 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $81.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609533 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $95.76 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609535 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $81.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609537 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $95.81 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609539 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $81.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609541 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $95.76 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609543 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $81.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609545 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $81.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609547 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $81.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609549 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $81.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609551 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $95.76 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609553 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $81.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609555 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $95.76 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609557 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $81.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609559 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $81.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223615834 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $337.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223615836 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $240.00 | 07/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223615838 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,197.00 | 07/09/2025 | Non-covered Recipient Entity CHILDRENS HOSPITAL OF THE KINGS DAUGHTERS INC | A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy | No dispute reported | 06/30/2026 | 1190305129 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,936.25 | 07/07/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9004-102 | No dispute reported | 06/30/2026 | 1223615770 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $945.00 | 07/07/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9004-102 | No dispute reported | 06/30/2026 | 1223615772 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $337.00 | 07/07/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9004-102 | No dispute reported | 06/30/2026 | 1223615774 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $767.48 | 07/07/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9004-102 | No dispute reported | 06/30/2026 | 1223615776 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $2,386.26 | 06/30/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP PLLC | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249093455 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 06/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613081 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 06/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611323 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $38,281.18 | 06/20/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9004-102 | No dispute reported | 06/30/2026 | 1223611143 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 06/18/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611315 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 06/18/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611333 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.24 | 06/11/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223612927 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.28 | 06/11/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223612929 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.02 | 06/11/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223612931 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $9.26 | 06/11/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223612933 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $59.14 | 06/11/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223612935 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,524.07 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611305 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611307 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611309 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611311 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611313 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $3,812.71 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611317 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,422.09 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611321 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611325 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611327 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611331 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,524.07 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613079 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613083 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $26,666.15 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613085 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613087 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $3,812.71 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613093 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 06/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613095 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 06/02/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611319 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 06/02/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611329 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $817.39 | 06/02/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223613089 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $630.00 | 06/02/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223613091 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $1,223.78 | 05/30/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP PLLC | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249093417 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $6,472.82 | 05/26/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611239 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $6,472.82 | 05/26/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611243 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,500.00 | 05/22/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP | Phase IIIb, Open-label, Single-arm, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally (1.2 x 10^14 Vector Genomes) to Participants 2 to 12 Years of Age With Spinal Muscular Atrophy (SMA) Who Have Dis | No dispute reported | 06/30/2026 | 1190300235 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,751.97 | 05/21/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-401 | No dispute reported | 06/30/2026 | 1223612961 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $12.62 | 05/20/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223613989 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.36 | 05/16/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613973 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.42 | 05/16/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613975 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.03 | 05/16/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613977 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $13.89 | 05/16/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613979 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $88.71 | 05/16/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613981 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $22.90 | 05/15/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613983 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $166.88 | 05/15/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613985 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $30.42 | 05/15/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613987 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,000.00 | 05/07/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223611241 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,304.85 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612177 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $11,455.69 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612179 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,394.26 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612181 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612183 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,304.85 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612185 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $916.99 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223612187 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $9,846.87 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612189 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,685.00 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612191 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,438.85 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612193 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613919 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613921 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,079.14 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613923 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $504.91 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613925 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,079.14 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613927 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613929 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,438.85 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613931 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,079.13 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613933 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613935 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613937 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $26,666.15 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613939 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $809.34 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613941 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613943 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,394.26 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613945 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,524.07 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613947 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $9,846.87 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613949 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $809.34 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613951 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613953 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,079.14 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223613955 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $11,455.69 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223615573 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223615575 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,079.14 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223615577 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223615579 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $11,455.69 | 04/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223615581 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $37.37 | 04/28/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-103 | No dispute reported | 06/30/2026 | 1223610291 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $77,344.33 | 04/10/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP, PLLC | An Open-Label, Single-arm Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, and Efficacy of Gefurulimab in Pediatric Patients (6 to < 18 years of age) with Generalized Myasthenia Gravis (gMG) Who Express Acetylcholine Receptor Antibodies (AChR+) | No dispute reported | 06/30/2026 | 1185553665 |
| Recipient | F. Hoffmann-La Roche AG | $965.12 | 03/31/2025 | Covered Recipient Physician | A PHASE II STUDY OF SATRALIZUMAB IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1211535229 |
| Recipient | F. Hoffmann-La Roche AG | $435.13 | 03/31/2025 | Covered Recipient Physician | A PHASE II STUDY OF SATRALIZUMAB IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1211535233 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $16,956.54 | 03/26/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9003-301 | No dispute reported | 06/30/2026 | 1223609027 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $6.18 | 03/26/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223609113 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $85.38 | 03/26/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223609115 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $18.31 | 03/26/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223609117 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $4.57 | 03/26/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223609119 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $916.99 | 03/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609971 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $916.99 | 03/24/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223609973 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $2,395.00 | 03/17/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP PLLC | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249093275 |
| Recipient | Novartis Pharma AG | $212.44 | 03/15/2025 | Covered Recipient Physician | COAV101A12001 | No dispute reported | 06/30/2026 | 1248109681 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $10,346.73 | 03/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-LGMD-501-NHS | No dispute reported | 06/30/2026 | 1223609023 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $8,022.10 | 03/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-LGMD-501-NHS | No dispute reported | 06/30/2026 | 1223609025 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $7,255.42 | 03/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-LGMD-501-NHS | No dispute reported | 06/30/2026 | 1223615358 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $62,283.70 | 03/03/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9004-102 | No dispute reported | 06/30/2026 | 1223609029 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,323.39 | 02/28/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223611939 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,022.00 | 02/27/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP | A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101 | No dispute reported | 06/30/2026 | 1190308700 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $470.00 | 02/27/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP PLLC | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249093221 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.24 | 02/14/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611941 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.28 | 02/14/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611943 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.02 | 02/14/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611945 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $65.46 | 02/14/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611947 |
| Principal investigator 1 | Biogen, Inc. | $72,686.80 | 02/12/2025 | Non-covered Recipient Entity CHKD Main Hospital | An Open Label, Single Cohort Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered Via the ThecaFlex DRx System (PIERRE-PK) | No dispute reported | 06/30/2026 | 1236947274 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 02/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612773 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,394.26 | 02/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612775 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 02/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612777 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 02/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612779 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $3,812.71 | 02/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612781 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 02/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612783 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 02/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612785 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,304.85 | 02/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612787 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 02/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612789 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $321.66 | 02/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612791 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 02/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612793 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $418.29 | 02/05/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223612795 |
| Principal investigator 1 | Genentech, Inc. | $16,875.00 | 01/30/2025 | Non-covered Recipient Entity Childrens Specialty Group PLLC | Risdiplam post gene therapy study treatment prophylactically study 1 | No dispute reported | 06/30/2026 | 1211586299 |
| Recipient | Novartis Pharmaceuticals Corporation | $9,621.58 | 01/30/2025 | Covered Recipient Physician | STEER | No dispute reported | 06/30/2026 | 1190293712 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $916.99 | 01/30/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614499 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $17,297.05 | 01/29/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9004-102 | No dispute reported | 06/30/2026 | 1223609031 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,085.39 | 01/29/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614493 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $916.99 | 01/29/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614495 |
| Principal investigator 1 | Genentech, Inc. | $15,525.00 | 01/28/2025 | Non-covered Recipient Entity Childrens Specialty Group PLLC | A PHASE II STUDY OF SATRALIZUMAB IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1211586283 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1.00 | 01/28/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610029 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $256.14 | 01/28/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610031 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $893.52 | 01/27/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-303 | No dispute reported | 06/30/2026 | 1223610019 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.72 | 01/27/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610021 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.84 | 01/27/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610023 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.06 | 01/27/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610025 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $98.19 | 01/27/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610027 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,565.50 | 01/23/2025 | Non-covered Recipient Entity CHILDRENS HOSPITAL OF THE KINGS DAUGHTERS INC | A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy | No dispute reported | 06/30/2026 | 1190305125 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $6,472.82 | 01/10/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614497 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $630.00 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614489 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $506.72 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614491 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $194.14 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614501 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $194.14 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614503 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $203.78 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614505 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $570.06 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614507 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $594.78 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614509 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $203.78 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614511 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $61.95 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614513 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $203.78 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614515 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $467.09 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614517 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $433.68 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614519 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $570.06 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614521 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $467.09 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614523 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $945.00 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614525 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $61.95 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614527 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $61.95 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614529 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $194.14 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614531 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $495.63 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223614533 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $557.59 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223615360 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $557.59 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223615362 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $594.78 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223615364 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $5,355.00 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223615366 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $61.95 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223615368 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $557.59 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223615370 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $528.70 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223615372 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $194.14 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223615374 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $570.06 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223615376 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $594.78 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223615378 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $467.09 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223615380 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $203.82 | 01/09/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223615382 |
| Principal investigator 1 | Biogen, Inc. | $1,369.00 | 01/07/2025 | Covered Recipient Teaching Hospital Childrens Hospital Of The Kings Da | A Phase 4 Study of Nusinersen (BIIB058) Among Patients With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec | No dispute reported | 06/30/2026 | 1236947602 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $425.26 | 01/07/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610015 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $18.96 | 01/07/2025 | Non-covered Recipient Entity CHILDREN'S SPECIALTY GROUP, PLLC | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223610017 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,269.00 | 01/01/2025 | Non-covered Recipient Entity CHILDRENS HOSPITAL OF THE KINGS DAUGHTERS INC | Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 IT or OAV101 IV in Clinical Trials | No dispute reported | 06/30/2026 | 1190305133 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,176.90 | 01/01/2025 | Non-covered Recipient Entity CHILDRENS HOSPITAL OF THE KINGS DAUGHTERS INC | A Randomized, Sham-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Intrathecal OAV101 in Patients Type 2 Spinal Muscular Atrophy (SMA) Who Are 2 to < 18 Years of Age, Treatment Naive, Sitting, and Never Ambulatory | No dispute reported | 06/30/2026 | 1190305135 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $805.30 | 01/01/2025 | Non-covered Recipient Entity CHILDRENS HOSPITAL OF THE KINGS DAUGHTERS INC | Phase IIIb, Open-label, Single-arm, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally (1.2 x 10^14 Vector Genomes) to Participants 2 to 12 Years of Age With Spinal Muscular Atrophy (SMA) Who Have Dis | No dispute reported | 06/30/2026 | 1190305139 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $45,473.65 | 01/01/2025 | Non-covered Recipient Entity CHILDRENS SPECIALTY GROUP PLLC | A Phase 1/2, Randomized, Double-blind, Placebo?controlled Single- and Multiple?dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX?670 in Adult Subjects with Myotonic Dystrophy Type 1 | No dispute reported | 06/30/2026 | 1214123812 |